Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CELLCEPT vs AZATHIOPRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.
Prophylaxis of organ rejection in renal transplant recipients,Prophylaxis of organ rejection in cardiac transplant recipients,Prophylaxis of organ rejection in hepatic transplant recipients,Off-label: Treatment of lupus nephritis, autoimmune diseases, and other transplant indications
Renal transplant rejection prophylaxis (FDA),Rheumatoid arthritis (FDA),Off-label: autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's disease, ulcerative colitis), pemphigus, myasthenia gravis, dermatomyositis/polymyositis,Off-label: myelodysplastic syndrome, refractory immune thrombocytopenic purpura, atopic dermatitis, Behçet's syndrome
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Terminal elimination half-life of azathioprine is approximately 2–5 hours; its active metabolite 6-mercaptopurine has a half-life of 1–2 hours, but 6-thioguanine nucleotides accumulate in red blood cells with a half-life of several days, correlating with myelosuppression.
Mycophenolate mofetil is hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is primarily metabolized by glucuronidation via UDP-glucuronosyltransferases (UGT1A9 and UGT2B7) to MPA-glucuronide (MPAG), which is excreted in urine.
Azathioprine is metabolized by xanthine oxidase (XO) and thiopurine methyltransferase (TPMT) to active (6-mercaptopurine) and inactive metabolites. 6-Mercaptopurine is further metabolized by XO to 6-thiouric acid and by TPMT to 6-methylmercaptopurine. Genetic deficiency of TPMT increases risk of toxicity.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Renal (approximately 2% as unchanged drug, 30% as 6-thiouric acid and other metabolites); biliary/fecal (minor, <10% as metabolites).
97% bound to albumin. In renal impairment or hypoalbuminemia, free fraction increases.
Approximately 30% bound, primarily to albumin.
Apparent volume of distribution of MPA is approximately 3.6 L/kg (range 1.5-5.0 L/kg), indicating extensive tissue distribution.
0.8–1.0 L/kg, indicating distribution into total body water; extensive distribution into tissues including liver and erythrocytes.
Oral bioavailability of mycophenolate mofetil is approximately 94% (converted to MPA). Intravenous: 100%.
Oral bioavailability of azathioprine is 60–80% (mean 70%) with interindividual variability; absorption may be reduced by food.
For GFR 10-50 m L/min: maximum 2 g daily; for GFR <10 m L/min: maximum 1 g daily.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer 75% of normal dose. GFR <10 m L/min: administer 50% of normal dose. Hemodialysis: administer 50% of normal dose after dialysis.
No dosage adjustment required for hepatic impairment. No Child-Pugh based modifications are established.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: contraindicated or use with extreme caution; reduce dose by at least 50%.
For ages 3 months to 18 years: 600 mg/m2 orally twice daily; maximum 2 g daily. Intravenous: same oral dose converted to IV.
1.5 to 2.5 mg/kg orally once daily; maximum 150 mg/day. For inflammatory bowel disease: 2-3 mg/kg/day. Intravenous: 3-5 mg/kg/day as a slow infusion.
No specific dose adjustment, but start at lower end of dosing range due to age-related renal impairment. Monitor for adverse effects.
Initiate at lower end of dosing range (1.5 mg/kg/day) due to potential for decreased renal and hepatic function; monitor renal function and hematologic parameters closely.
Increased risk of pregnancy loss and congenital malformations; must avoid pregnancy during therapy. Use in women of childbearing potential only if contraception is used and pregnancy is excluded.
Malignancy: Patients receiving immunosuppressive therapy including azathioprine have an increased risk of developing lymphoma and other malignancies, particularly skin cancers. The risk is related to the duration and intensity of immunosuppression. Hematologic toxicity: Severe leukopenia, thrombocytopenia, and anemia, which may be dose-related, can occur. Regular monitoring of blood counts is required. Hepatotoxicity: Hepatotoxicity, including fatal liver injury, has been reported, particularly at high doses.
Increased susceptibility to infections (e.g., CMV, BK virus), lymphomas, and other malignancies; dose reduction in renal impairment; avoid use with azathioprine; monitor for neutropenia, GI bleeding, and progressive multifocal leukoencephalopathy.
Hematologic monitoring: regular CBCs; Increased risk of infection; Hepatotoxicity; Pancreatitis; Carcinogenicity (lymphoma, skin cancer); TPMT deficiency increases myelotoxicity; Vaccination (live vaccines contraindicated); Renal and hepatic impairment; Drug interactions: allopurinol (reduce dose by 75%), ACE inhibitors (anemia), warfarin (anticoagulant effect decreased).
Hypersensitivity to mycophenolate mofetil or mycophenolic acid; women who are pregnant or planning pregnancy (unless no alternative); women of childbearing potential not using effective contraception.
Hypersensitivity to azathioprine or 6-mercaptopurine; Pregnancy (unless benefit outweighs risk) - Category D; Lactation; Patients with TPMT deficiency (increased risk of severe myelotoxicity); Severely depressed bone marrow function; Active infections; Concurrent use of live vaccines; Pre-existing malignancy (except in organ transplantation context).
Avoid taking with food high in fat or protein as it may reduce absorption. Grapefruit juice may decrease mycophenolate absorption; avoid concurrent consumption. No specific dietary restrictions besides maintaining consistent intake with meals.
No known significant food interactions. Avoid grapefruit juice? (No interaction reported). Maintain consistent diet; no specific restrictions. Limit alcohol due to hepatotoxicity risk.
First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube defects. Second and third trimester exposure may cause intrauterine growth restriction, preterm delivery, and neonatal immunosuppression. Mycophenolic acid is contraindicated in pregnancy unless no alternative treatment is available.
Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and third trimesters: risk of intrauterine growth restriction, preterm birth, and neonatal immunosuppression (leukopenia, thrombocytopenia). Use only if benefit outweighs risk.
M/P ratio is unknown. Mycophenolic acid is excreted into breast milk in small amounts; however, due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth delay, breastfeeding is not recommended during therapy.
Azathioprine is excreted into breast milk in low concentrations. M/P ratio is approximately 0.7. Nursing infants of mothers on azathioprine have not shown adverse effects; however, theoretical risk of immunosuppression exists. Caution is advised; monitor infant for increased infections.
No specific dose adjustments are established due to lack of pharmacokinetic data in pregnancy. Systemic exposure may be reduced due to increased plasma volume and metabolism; however, due to teratogenicity, use is contraindicated. If unavoidable, consider monitoring mycophenolic acid trough levels and adjust dose to maintain therapeutic range (1.0–3.5 mg/L), but safety is not established.
Pharmacokinetic changes in pregnancy include increased clearance and decreased absorption. Dose may need adjustment to maintain therapeutic efficacy. Close monitoring of disease activity and drug levels (6-thioguanine nucleotide levels) is recommended. No standard dose adjustment; individualization required.
Mycophenolate mofetil (CELLCEPT) is a prodrug of mycophenolic acid, an inosine monophosphate dehydrogenase inhibitor. It is used for prophylaxis of organ rejection in renal, cardiac, and hepatic transplant recipients. Monitor for leukopenia, neutropenia, and infections. Dose adjustment required in renal impairment (GFR <25 m L/min). Avoid use in pregnancy (Pregnancy Category D). Contraindicated in hypersensitivity to mycophenolate. Intravenous administration should be over 2 hours. Monitor for GI bleeding and CMV infection.
Monitor CBC and LFTs weekly for first month, then biweekly for 2 months, then monthly. TPMT genotype testing before initiation. Avoid concurrent allopurinol unless dose reduced to 25% of original. Use with caution in renal impairment. May cause hepatotoxicity, pancreatitis, or lymphoproliferative disorders.
Take exactly as prescribed, with or without food. Do not crush or chew capsules.,Avoid sunlight and use sunscreen due to increased risk of skin cancer.,Report any signs of infection (fever, sore throat, unusual bleeding or bruising).,Use effective contraception during treatment and for 6 weeks after stopping if female of childbearing potential.,Do not breastfeed while taking this medication.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not double dose if missed.,Avoid live vaccines during treatment and for 3 months after stopping.,Report any signs of infection, unexplained bruising/bleeding, or jaundice immediately.,Limit sun exposure and use sunscreen due to increased skin cancer risk.,Do not take allopurinol or other new medications without consulting doctor.,Maintain adequate hydration to reduce risk of hepatotoxicity.,Regular blood tests are required to monitor for side effects.
No interactions on record
"Azathioprine may reduce the therapeutic efficacy and cardiotoxic effects of digitoxin by accelerating its metabolism through induction of cytochrome P450 enzymes, particularly CYP3A4. This interaction can lead to decreased digitoxin serum concentrations, potentially resulting in loss of heart rate control in patients with atrial fibrillation or heart failure. Conversely, the cardiotoxic risk of digitoxin is diminished, but the therapeutic goal may be compromised."
"Azathioprine and fingolimod both suppress lymphocyte function, leading to additive or synergistic immunosuppression. This combination increases the risk of severe infections, including opportunistic infections, due to profound immune system suppression. Clinically, patients may present with prolonged lymphopenia, increased susceptibility to infections, and potential reactivation of latent viruses such as JC virus (causing progressive multifocal leukoencephalopathy) or cytomegalovirus."
"Azathioprine, an immunosuppressant that acts as a prodrug for 6-mercaptopurine, can increase the myelosuppressive effects of benazepril, an ACE inhibitor. This interaction is likely due to additive bone marrow suppression, leading to an elevated risk of leukopenia, anemia, and thrombocytopenia, especially in patients with renal impairment or concomitant use of other myelosuppressive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CELLCEPT vs AZATHIOPRINE, answered by our medical review team.
CELLCEPT is a Immunosuppressant that works by Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.. AZATHIOPRINE is a Immunosuppressant that works by Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CELLCEPT and AZATHIOPRINE depend on the specific clinical indication. These are both Immunosuppressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CELLCEPT is: Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.. The standard adult dose of AZATHIOPRINE is: 1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CELLCEPT and AZATHIOPRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CELLCEPT is classified as Category C. First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube de. AZATHIOPRINE is classified as Category D/X. Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.